Great discussion by Dr. Rebecca Heist (@MassGeneralBrigham) at #ESMO2026 summarizing key Phase III trials targeting acquired resistance in EGFRm NSCLC! 🧬

Key takeaways on EGFR + MET TKI strategies:
▪️ SAFFRON (Osi + Savo vs Chemo): PFS 7.6 vs 5.4 mo (HR 0.55), OS 17.8 vs 12.9 mo (HR 0.68) post-3rd gen TKI.
▪️ SACHI (Osi + Savo): PFS 8.2 vs 4.5 mo (HR 0.34) | ORR 63% vs 36%.
▪️ MARIPOSA-2 Benchmarking: Ami-chemo gives PFS 8.3 vs 4.2 mo (HR 0.44), but without MET selection.

Dr. Heist highlighted critical open questions: defining optimal MET cutoffs, balancing oral vs IV regimens, and distinct AE profiles across combinations! 
#LungCancer #OncoX #ESMO26 #NSCLC